Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

Apr 15, 2014 at 5:29PM

In just a few months Isis Pharmaceuticals (NASDAQ:IONS) has gone from investment darling to investment dog, dropping nearly 20% since the beginning of this year.

But little has changed at Isis, suggesting the recent move lower is tied more to profit-taking and momentum than to long term opportunities stemming from the company's antisense technology. Given that backdrop, lets take a closer look at Isis and see whether the share slide is justified.

ISIS Chart

ISIS data by YCharts

Making sense out of antisense
Gene therapy is one of the most exciting areas of biotechnology research and development. The concept is simple. Identify over- or under-active genes and develop drugs that return them to their normal levels of activity.

Across the biotech industry, few have been as prolific as Isis in coming up with disease targets and potential new treatments. That success stems from Isis' unique drug discovery platform and RNAi-targeting technologies, which allow drugs to bind with genes rather than proteins.

Despite the specificity of targeting one gene, antisense drugs' ability to accumulate in organs like the liver and kidney suggest that developing drugs that target RNA in those organs may allow antisense drugs to treat a wide variety of diseases.

As a result, Isis' pipeline is chock-full of intriguing clinical stage drugs that may eventually reach the market.

Pumped up pipeline
Isis has more than 30 ongoing trials across a variety of diseases including cardiovascular, cancerous, and inflammatory conditions. Among those programs, the closest to reaching the market are drugs for TTR amyloidosis and prostate cancer.

TTR amyloidosis is a rare disease. In healthy patients, the TTR protein helps transport vitamin A around the body. In patients where the TTR gene is mutated, mis-folded TTR proteins accumulate in tissues such as peripheral nerves or the heart. While there are over 100 mutations of the TTR gene, cases are categorized as either familial amyloidotic polyneuropathy, or FAP, and familial amyloidotic cardiomyopathy, or FAC.

Globally, estimates peg the FAP patient population at just 10,000 and the FAC patient population at about 40,000. Since the disease has a poor prognosis, there's a significant unmet need and opportunity for ISIS-TTRrx, which is currently in phase 2/3 studies.

As a result, GlaxoSmithKline (NYSE:GSK) agreed to partner with Isis on ISIS-TTRrx, committing to paying Isis up to $50 million in milestone payments associated with the current phase 2b trial. Additionally, Glaxo boosted its previously planned regulatory and sales milestone payments to Isis in 2012 and agreed to pay Isis double-digit royalties on any eventual sales of ISIS-TTRrx.

In order for Glaxo and Isis to capture the market share opportunity in TTR, they will need to outmaneuver RNAi competitor Alnylam (NASDAQ:ALNY)Alnylam is also working on a promising compound, patisiran, for FAP, and that drug, which is being co-developed by Sanofi's Genzyme, is currently being studied in phase 3 trials.  

Isis also has a well-heeled partner in Teva Pharmaceuticals (NYSE:TEVA) on Custirsen, a potential adjunct therapy for metastatic prostate cancer. If Custirsen succeeds in its current phase 3 trials, the drug could capture sales as a first line treatment dosed alongside docetaxel in mCRPC patients. Data from that trial is expected this year, but investors should watch Teva's other ongoing study of Custirsen as part of a treatment regimen for non small cell lung cancer too.

Fool-worthy final thoughts
The ability to commercialize antisense technology isn't science fiction. The company and its development partner Sanofi are already marketing a cholesterol battling compound, Kynamro.

So far, Kynamro sales have been small. The drug is currently only approved to treat patients with homozygous familial hypercholesterolemia, or HoFH, a small population of people with high bad cholesterol levels that are resistant to other treatment. As a result, Isis isn't even breaking out its share of royalties from Kynamro sales yet. But the drug should continue to see sales climb, especially if late stage studies in heterozygous hypercholesterolemia pan out. While there are less than 350 people in the U.S. with HoFH, there are as many as 600,000 cases of HeFH.

Given the company's substantial pipeline, there's plenty of news coming that may cause Isis shares to move up or down this year. Investors interested in antisense companies need to consider owning Isis given its leadership position, but should recognize Isis shares will continue to come with plenty of volatility.

These 6 stock picks may offer a clearer path to profit
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Todd Campbell is long Isis Pharmaceuticals. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Alnylam Pharmaceuticals, Isis Pharmaceuticals, and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers